{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:30:09Z","timestamp":1771007409969,"version":"3.50.1"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to investigate whether the specific T cell response against the multiple myeloma Ag HM1.24 is enhanced by the immunomodulatory drug lenalidomide (Revlimid). Ag-specific CD3+CD8+ T cells against the HM1.24 Ag were expanded in vitro by dendritic cells in 29 healthy donors and 26 patients with plasma cell dyscrasias. Ag-specific activation was analyzed by IFN-\u03b3, granzyme B, and perforin secretion using ELISA, ELISPOT assay, and intracellular staining, and generation of Ag-specific T cells was analyzed by tetramer staining. Expression of T cell maturation markers (CD45RA, CD45R0, CCR7, and CD28) was investigated by flow cytometry. We found that activation of HM1.24-specific T cells from healthy donors and patients with plasma cell dyscrasias was enhanced significantly by lenalidomide and furthermore that the impact of lenalidomide on T cells depends on the duration of the exposure. Notably, lenalidomide supports the downregulation of CD45RA on T cells upon activation, observed in healthy donors and in patients in vitro and also in patients during lenalidomide therapy in vivo. We showed for the first time, to our knowledge, that lenalidomide enhances the Ag-specific activation of T cells and the subsequent downregulation of CD45RA expression of T cells in vitro and in vivo.<\/jats:p>","DOI":"10.4049\/jimmunol.1002460","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T13:45:17Z","timestamp":1308231917000},"page":"1047-1056","source":"Crossref","is-referenced-by-count":36,"title":["Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma"],"prefix":"10.1093","volume":"187","author":[{"given":"Brigitte","family":"Neuber","sequence":"first","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Herth","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Tolliver","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Schoenland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]},{"name":"National Center for Tumor Diseases, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]},{"name":"National Center for Tumor Diseases, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[{"name":"INSERM , U847, F-34197 Montpellier ,","place":["France France"]},{"name":"Centre Hospitalier Universitaire de Montpellier, Institut de Recherche en Bioth\u00e9apies , F-34285 Montpellier ,","place":["France"]},{"name":"Unit\u00e9 de Formation et de Recherche de M\u00e9decine, Universit\u00e9 Montpellier1 , F-34967 Montpellier ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg , 69120 Heidelberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,7,15]]},"reference":[{"key":"2025032410210433500_r1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"2025032410210433500_r2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10428190500272473","article-title":"Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation","volume":"47","author":"Bendandi","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"2025032410210433500_r3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.exphem.2006.01.008","article-title":"Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma","volume":"34","author":"Hundemer","year":"2006","journal-title":"Exp. Hematol."},{"key":"2025032410210433500_r4","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2004-01-0366","article-title":"Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma","volume":"105","author":"Choi","year":"2005","journal-title":"Blood"},{"key":"2025032410210433500_r5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood.V94.2.673","article-title":"Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy","volume":"94","author":"Massaia","year":"1999","journal-title":"Blood"},{"key":"2025032410210433500_r6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1046\/j.1365-2141.2000.01958.x","article-title":"Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects","volume":"108","author":"Titzer","year":"2000","journal-title":"Br. J. Haematol."},{"key":"2025032410210433500_r7","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2002-06-1925","article-title":"Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells","volume":"101","author":"Rasmussen","year":"2003","journal-title":"Blood"},{"key":"2025032410210433500_r8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.2007.06832.x","article-title":"Phase I\/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides","volume":"139","author":"Curti","year":"2007","journal-title":"Br. J. Haematol."},{"key":"2025032410210433500_r9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/j.1460-2075.1993.tb05664.x","article-title":"Clonal deletion of specific thymocytes by an immunoglobulin idiotype","volume":"12","author":"Bogen","year":"1993","journal-title":"EMBO J."},{"key":"2025032410210433500_r10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/(SICI)1097-0215(19981005)78:2<216::AID-IJC16>3.0.CO;2-8","article-title":"Clonal deletion of thymocytes as a tumor escape mechanism","volume":"78","author":"Lauritzsen","year":"1998","journal-title":"Int. J. Cancer"},{"key":"2025032410210433500_r11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2141.2003.04789.x","article-title":"Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage","volume":"124","author":"Mozaffari","year":"2004","journal-title":"Br. J. Haematol."},{"key":"2025032410210433500_r12","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"2025032410210433500_r13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"key":"2025032410210433500_r14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-gamma and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"2025032410210433500_r15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/hum.2005.16.445","article-title":"Lentiviral transduction of primary myeloma cells with CD80 and CD154 generates antimyeloma effector T cells","volume":"16","author":"Cignetti","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"2025032410210433500_r16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.exphem.2006.11.002","article-title":"B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro","volume":"35","author":"Lu","year":"2007","journal-title":"Exp. Hematol."},{"key":"2025032410210433500_r17","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1038\/sj.leu.2401925","article-title":"Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro","volume":"14","author":"Tarte","year":"2000","journal-title":"Leukemia"},{"key":"2025032410210433500_r18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.leu.2403181","article-title":"Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy","volume":"18","author":"Coscia","year":"2004","journal-title":"Leukemia"},{"key":"2025032410210433500_r19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1078-0432.CCR-06-1603","article-title":"Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients","volume":"13","author":"Hansson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"2025032410210433500_r20","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1182\/blood.V99.12.4525","article-title":"Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Blood"},{"key":"2025032410210433500_r21","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2025032410210433500_r22","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","article-title":"Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"2025032410210433500_r23","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2025032410210433500_r24","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.0610477104","article-title":"Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients","volume":"104","author":"Pellagatti","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032410210433500_r25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk. Res."},{"key":"2025032410210433500_r26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","article-title":"Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells","volume":"67","author":"Verhelle","year":"2007","journal-title":"Cancer Res."},{"key":"2025032410210433500_r27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156800910791054239","article-title":"Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function","volume":"10","author":"Gandhi","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"key":"2025032410210433500_r28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J. Immunol."},{"key":"2025032410210433500_r29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","article-title":"Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma","volume":"98","author":"Davies","year":"2001","journal-title":"Blood"},{"key":"2025032410210433500_r30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/368126","article-title":"Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro","volume":"187","author":"Haslett","year":"2003","journal-title":"J. Infect. Dis."},{"key":"2025032410210433500_r31","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2025032410210433500_r32","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia","volume":"94","author":"Aue","year":"2009","journal-title":"Haematologica"},{"key":"2025032410210433500_r33","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1158\/1078-0432.CCR-07-5290","article-title":"Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy","volume":"14","author":"Song","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"2025032410210433500_r34","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2025032410210433500_r35","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"2025032410210433500_r36","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032410210433500_r37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2009-02-200543","article-title":"Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases","volume":"114","author":"Xu","year":"2009","journal-title":"Blood"},{"key":"2025032410210433500_r38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"2025032410210433500_r39","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"2025032410210433500_r40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/leu.2008.247","article-title":"Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells","volume":"23","author":"Minnema","year":"2009","journal-title":"Leukemia"},{"key":"2025032410210433500_r41","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","article-title":"Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs","volume":"305","author":"Schafer","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2025032410210433500_r42","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"2025032410210433500_r43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CJI.0b013e3181a95198","article-title":"Melan-A\/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24","volume":"32","author":"Christensen","year":"2009","journal-title":"J. Immunother."},{"key":"2025032410210433500_r44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1084\/jem.20020242","article-title":"Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2\/Melan-a peptide multimer(+) CD8(+) T cells in humans","volume":"196","author":"Dutoit","year":"2002","journal-title":"J. Exp. Med."},{"key":"2025032410210433500_r45","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-008-0867-7","article-title":"Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction","volume":"63","author":"Kumar","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2025032410210433500_r46","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"2025032410210433500_r47","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"2025032410210433500_r48","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1084\/jem.190.5.705","article-title":"High frequencies of naive Melan-A\/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals","volume":"190","author":"Pittet","year":"1999","journal-title":"J. Exp. Med."},{"key":"2025032410210433500_r49","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1006\/bbrc.1999.0683","article-title":"Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells","volume":"258","author":"Ohtomo","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2025032410210433500_r50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.jid.5700001","article-title":"Cytotoxic T cells","volume":"126","author":"Andersen","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"2025032410210433500_r51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10067-007-0786-8","article-title":"Thalidomide has both anti-inflammatory and regulatory effects in Behcet\u2019s disease","volume":"27","author":"Direskeneli","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"2025032410210433500_r52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2009.155","article-title":"Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells","volume":"45","author":"Lioznov","year":"2010","journal-title":"Bone Marrow Transplant."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/187\/2\/1047\/62474472\/1002460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/187\/2\/1047\/62474472\/1002460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T02:11:12Z","timestamp":1743127872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/187\/2\/1047\/7973794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,7,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1002460","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,7]]},"published":{"date-parts":[[2011,7]]}}}